Certain genetic variants, carried by around 10 percent of the population, could be making type 2 diabetes GLP-1 treatments (such as Ozempic and Wegovy) less effective, according to new research
Likewise, the wide cytoprotection agenda might also be distinctive from the focused background of the angiotensin-converting-enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers [45,46,47], or beta-blockers [48]
CJC-1295 (no DAC) supplies input (1)
So, the modern medical solution to this mismatch between the foods we were built to eat, that naturally activate satiety circuits, and the processed junk were now being sold is to physically, surgically change our anatomy to force it to the end of our gut, or inject GLP-1 mimicking drugs, so we get GLP-1 activation regardless of what we eat